Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor –tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).

Source: European Journal of Cancer - October 28, 2018 Category: Cancer & Oncology Authors: Matthew T. Campbell, Mehmet A. Bilen, Amishi Y. Shah, Emily Lemke, E. Jonasch, A.M. Venkatesan, E. Altinmakas, C. Duran, Pavlos Msaouel, N.M. Tannir Tags: Original Research Source Type: research